Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE:AGN)…

Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

VANCOUVER, British Columbia, May 06, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

ANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

VANCOUVER, British Columbia, April 22, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil Intravenous Formulation

VANCOUVER, British Columbia, April 15, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board

VANCOUVER, British Columbia, April 13, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE:…